How Will Johnson & Johnson's Opioid Case Ruling Impact Big Pharma Stocks?
Investors need to be careful about which pharmaceutical stocks they own.
Allergan
AGN
AGN
$172.50
$1.58
0.9%
BATS BZX Real Time Price as of October 17, 2019, 4:00 p.m. EDT
View Interactive AGN Charts
The Company is engaged in the development, manufacture, marketing, sale and distribution of brand and off-patent pharmaceutical products.
News & Analysis: Allergan
The Fool has written over 300 articles on Allergan.
Allergan Boosts 2019 Guidance While Waiting to be Acquired by AbbVie
The drugmaker's Q2 revenue and earnings beats enable it to raise full-year guidance.
Is Allergan a Buy?
You might think it's too late to profit with this soon-to-be-acquired drug stock. Think again.
Is AbbVie a Buy?
Is AbbVie's stock a bargain now that it's tying up with Botox maker Allergan?
Here's Why Nobody's Happy About This $63 Billion Buyout
AbbVie's buying Allergan for around $63 billion, and shareholders from both companies are not on board.
What Happened in the Stock Market Today
AbbVie became the latest player to pursue a pharma megadeal, and Lennar beat expectations for the second quarter.
Why AbbVie Stock Is Sinking and Allergan Is Soaring Today
Investors are cheering Allergan and jeering AbbVie after the announcement of a major acquisition.
AbbVie’s $63 Billion Mistake
Overpaying for Allergan would be a serious misstep.
What You Need to Know About Allergan's Solid Q1 Performance
Here's why the drugmaker topped revenue and earnings expectations in Q1.
Allergan PLC (AGN) Q1 2019 Earnings Call Transcript
AGN earnings call for the period ending May 7, 2019.
